AlphaQuest LLC Has $29,000 Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

AlphaQuest LLC reduced its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 94.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 516 shares of the specialty pharmaceutical company’s stock after selling 9,377 shares during the period. AlphaQuest LLC’s holdings in ANI Pharmaceuticals were worth $29,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. State Street Corp boosted its position in shares of ANI Pharmaceuticals by 9.1% during the 3rd quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock valued at $41,991,000 after acquiring an additional 58,698 shares in the last quarter. Global Alpha Capital Management Ltd. boosted its position in shares of ANI Pharmaceuticals by 16.4% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company’s stock valued at $34,525,000 after acquiring an additional 88,100 shares in the last quarter. Pacer Advisors Inc. boosted its position in shares of ANI Pharmaceuticals by 23,259.8% during the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock valued at $33,907,000 after acquiring an additional 565,910 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of ANI Pharmaceuticals by 159.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after acquiring an additional 340,854 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of ANI Pharmaceuticals by 4.2% during the 3rd quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock valued at $25,373,000 after acquiring an additional 17,314 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Price Performance

Shares of ANIP stock opened at $64.26 on Friday. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $70.81. The firm’s 50 day moving average is $59.39 and its 200-day moving average is $58.17. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of -116.84 and a beta of 0.63. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

Analyst Ratings Changes

A number of research firms have commented on ANIP. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a “buy” rating and a $80.00 price target on the stock. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 price target on the stock. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target on the stock. Finally, Guggenheim boosted their price target on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $79.75.

Insider Buying and Selling

In related news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the sale, the senior vice president now directly owns 66,525 shares of the company’s stock, valued at $4,048,711.50. The trade was a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Meredith Cook sold 400 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,200 shares of company stock valued at $191,776 over the last ninety days. Insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.